Corrections
A7i corrects errors and records what was corrected, when and why. Corrections remain on the record permanently. Where a figure previously published on this site has been revised, the original figure is stated so the change can be checked.
| Date | Scope | Was | Now, and why |
|---|---|---|---|
| 22 September 2026 | Site-wide dataAffects ctx-010, fac-010, wire-026 | Over 800,000 samples sequenced under the Emirati Genome Programme. | 780,000 UAE nationals took part in the programme, per its operator. The largest published analysis cohort is 43,608 individuals.The operator's figure measures participation, which is distinct from completed whole-genome sequencing. The record now states exactly what the primary source supports. |
| 22 September 2026 | Capital dataAffects ctx-002 | Public Investment Fund assets under management of $925bn, sourced to a third-party website. | $900bn+ for 2025, from the fund's own annual report.The figure now comes from the fund itself and sits in the context dataset, because assets under management measure a fund's scale rather than a capital transaction. |
| 22 September 2026 | Capital dataAffects ctx-003 | Hevolution Foundation has committed over $400m to aging research. | Hevolution Foundation committed more than $400m to healthspan science in the 21 months to June 2024. This is the most recent cumulative total published.The figure now carries its period, so the 2024 cumulative total reads as exactly that. |
| 22 September 2026 | Site-wide dataAffects fac-019, cli-011 | Five records sourced to PharmaKnowl, covering a Bahrain sector forecast, a GCC biologics market projection, Qatari stem-cell research spending, Omani contract manufacturing capability and a claim that Bahrain performed the first CRISPR gene therapy outside the United States. | All five removed. The Bahrain Oncology Centre and its CRISPR treatment remain on record as a monitored emerging signal, without the first-outside-the-United-States framing; the four market figures are removed entirely.Every record is held to A7i's source policy, which excludes PharmaKnowl. |
| 22 September 2026 | RegulationAffects regulation.Oman, wire-020 | Oman device registration mandatory before 1 July 2026. | A compliance deadline of six months from 22 April 2026 has been reported for imported medical devices. The 1 July 2026 date is withdrawn pending a Ministry of Health circular.The record now follows the reported six-month deadline, which carries a traceable source. |
| 22 September 2026 | RegulationAffects regulation.UAE | By 29 December 2025 the Emirates Drug Establishment had taken over 44 core regulatory services. | Held for confirmation by a primary source from the Emirates Drug Establishment.A specific date and count are published once they trace to a primary citation. |
| 22 September 2026 | RegulationAffects regulation.Bahrain | Bahrain's mandatory device registration deadline took effect 1 February 2026. | Held for confirmation by an NHRA source.The date is published once the authority confirms it. |
| 22 September 2026 | Capital data structureAffects capital.json, context.json | A single capital dataset containing sovereign assets under management, a 2040 GDP target, production capacity in units, healthcare expenditure forecasts and actual transactions. | Capital transactions are held in capital.json. Market sizes, fund sizes, targets, forecasts and capacity figures are held separately in context.json and kept apart from them in every sum.A GDP target and a Series A round now sit in separate datasets, so every chart compares like with like. |
| 22 September 2026 | WireAffects data/sources.json | Source attributions naming Mubadala Bio, Sidra Medicine, Lifera and the National Biotechnology Strategy against links to Zawya, a user-generated content platform, a dead URL and an Arab News article respectively. | Each source is attributed to the publisher that actually published it, with the underlying organisation named separately where relevant.Attribution to the actual publisher shows readers exactly where each claim appeared. |
| 22 September 2026 | WireAffects src-008, src-009, src-010, src-011 | Lifera press links at lifera.com.sa. | Links updated to lifera.com.The links now follow the company's move to its new domain. |
| 22 September 2026 | Infrastructure and capital dataAffects cap-010, fac-013, wire-019, src-022 | The DoH, M42, PureHealth and GEMMABio gene-therapy plan dated June 2026, with no indication named. | Dated 5 July 2025, the date of the Department of Health announcement, with spinal muscular atrophy type 1 recorded as the first indication.A link check against the authority's own release confirmed the announcement date. |
| 22 September 2026 | Companies and exportsAffects co-003, exp-004, fac-012, src-027 | Mubadala Bio recorded with an unspecified facility footprint. | 10 facilities, 6 in the Emirates, medicines reaching more than 100 countries, from the company's own launch release of 19 May 2025.The record now carries the figures from the company's primary release. |